These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4285635)

  • 1. Properties of a new type 3 attenuated poliovirus. V. Neurovirulence tests in monkeys after a passage through the human alimentary tract.
    Simon J; Vonka V; Janda Z
    Arch Gesamte Virusforsch; 1965; 15(5):681-9. PubMed ID: 4285635
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the characteristics of Poliovirus type 3. III. Strain characteristics after passage in man.
    Jarzabek Z; Sadowski W; Kańtoch M; Magrath D; Krawczyński K
    Acta Virol; 1976 Oct; 20(5):373-9. PubMed ID: 11664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROPERTIES OF A NEW ATTENUATED TYPE 3 POLIOVIRUS. II. NEUROVIRULENCE TESTS ON MONKEYS.
    SIMON J
    Arch Gesamte Virusforsch; 1965; 15():220-33. PubMed ID: 14269256
    [No Abstract]   [Full Text] [Related]  

  • 4. [ON THE NEUROVIRULENCE TEST OF LIVE POLIOVIRUS VACCINES. I. BASES, TECHNIC AND EVALUATION OF THE RESEARCH ON NEUROVIRULENCE MEASUREMENT IN MONKEYS].
    BONIN O; UNTERHARNSCHEIDT F
    Arch Psychiatr Nervenkr; 1964 Nov; 206():260-71. PubMed ID: 14344120
    [No Abstract]   [Full Text] [Related]  

  • 5. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of a new type 3 attenuated poliovirus. VI. Alimentary tract resistance in children fed previously with type 3 Sabin vaccine to reinfection with homologous and heterologous type 3 attenuated poliovirus.
    Janda Z; Adam E; Vonka V
    Arch Gesamte Virusforsch; 1967; 20(1):87-98. PubMed ID: 4299774
    [No Abstract]   [Full Text] [Related]  

  • 7. [Findings on the success of vaccination and revaccination with live and inactivated vaccines against poliomyelitis].
    Dostal V; Haenzel I; Sturm W
    Schweiz Med Wochenschr; 1969 Sep; 99(37):1322-4. PubMed ID: 4309326
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sabin poliovirus vaccine on incidence of poliomyelitis in Italy.
    Giovanardi A
    JAMA; 1969 Jul; 209(4):525-8. PubMed ID: 4307421
    [No Abstract]   [Full Text] [Related]  

  • 10. A STUDY OF SABIN TYPE 1 ORAL VACCINE VIRUS DURING FIVE HUMAN PASSAGES.
    PAVILANIS V; LUSSIER G; FOLEY AR; CHARBONNEAU JH; DIFRANCO E; DUBREUIL R
    Rev Can Biol; 1964 Sep; 23():265-76. PubMed ID: 14237159
    [No Abstract]   [Full Text] [Related]  

  • 11. A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine.
    Vonka V; Janda Z; Simon J; Adam E; Stárek M
    Prog Med Virol; 1967; 9():204-55. PubMed ID: 4293687
    [No Abstract]   [Full Text] [Related]  

  • 12. [Studies on safety tests of inactivated poliomyelitis vaccines. V. Pathomorphological changes in the CNS of rhesus monkeys (Macaca rhesus) and long-tailed monkeys (Cercopithecus aethiops) following intracerebral and intralumbar inoculation with inactivated poliovirus types I, II, and 3].
    Unterharnscheidt F; Günther O; Hövel H; Burde K; Heber L
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):150-66. PubMed ID: 4296871
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus.
    Bull World Health Organ; 1969; 40(6):925-45. PubMed ID: 4310724
    [No Abstract]   [Full Text] [Related]  

  • 14. Fractional-dose inactivated poliovirus vaccination campaign, Telangana state, India, June 2016.
    Wkly Epidemiol Rec; 2016 Aug; 91(34):397-403. PubMed ID: 27576292
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity and fecal poliovirus excretion in sequential use of inactivated and oral poliovirus vaccines.
    Lu CY; Kao CL; Lee CY; Lee PI; Huang LM
    J Formos Med Assoc; 2001 Aug; 100(8):513-8. PubMed ID: 11678000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of attenuated polio vaccine strains in a community immunized with inactivated polio vaccine.
    Rossier E; Phipps PH; Pépin O
    Dev Biol Stand; 1979; 43():179-85. PubMed ID: 520669
    [No Abstract]   [Full Text] [Related]  

  • 17. A clinical trial of Glenn type 3 attenuated poliovirus vacine.
    Barnes JM; Heymann CS; Galbraith NS; O'Moore GR
    Arch Gesamte Virusforsch; 1967; 20(3):296-304. PubMed ID: 4299730
    [No Abstract]   [Full Text] [Related]  

  • 18. The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines.
    Mon Bull Minist Health Public Health Lab Serv; 1965 Nov; 24():365-9. PubMed ID: 4286153
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
    Wood DJ
    Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEUROVIRULENCE FOR MONKEYS OF SABIN'S TYPE 1 POLIOVIRUS PASSED THROUGH HUMAN INTESTINES AS COMPARED WITH ATTENUATED AND VIRULENT POLIOVIRUS STRAINS.
    SIMON J
    J Hyg Epidemiol Microbiol Immunol; 1964; 8():506-15. PubMed ID: 14238949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.